Journal article

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim, Ravi Salgia, Panagiotis Fidias, Jeffrey A Engelman, Leena Gandhi, Pasi A Jaenne, Daniel B Costa, Geoffrey I Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson Show all

Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2012

Grants

Awarded by National Cancer Institute


Funding Acknowledgements

DRC, Y-JB, ELK, AJI, BS, S-HIO, D-WK, PAJ, DBC, PLR, and ATS received honoraria or consulting fees from Pfizer. ELK, GJR, BS, and JWC received research funding from Pfizer. AJI, MV-G, and GJR received honoraria or consulting fees from Abbott Molecular. GJR, LG, and ATS received honoraria or consulting fees from Chugai. GJR received research funding from Chugai, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Infinity Pharmaceuticals, and Merck; and honoraria or consulting fees from Daiichi and Tragara. GJR and ATS received honoraria or consulting fees from Novartis and Ariad and research funding from Novartis. PF received honoraria or consulting fees from Genentech. DBC received honoraria or consulting fees from AstraZeneca and Roche. KR, YT, and KW are employees and stockholders of Pfizer. ATS received research funding from AstraZeneca. SBF, RS, JAE, GIS, and PS declare that they have no conflicts of interest.We thank all the participating patients, their families, and the network of investigators, research nurses, study coordinators, and operations staff. The phase 1 clinical trial was sponsored by Pfizer. Investigators were supported in part by the National Cancer Institute P50-CA090578 (PAJ, DBC), the American Society of Clinical Oncology Conquer Cancer Foundation (DBC), and by internal funds from the Massachusetts General Hospital Cancer Center and Pathology Department (ATS, AJI). Editorial assistance was provided by Martin Quinn at Acumed (Tytherington, UK) and was funded by Pfizer.